Skip to content
Shuttingdown

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Pharmaceutical Preparations · CUPERTINO · CA

Distress signal

Moderate confidence (50%)

Updated Sep 21, 2026, 12:04 AM

What is happening

Derived by rule set status-rules-2026.09.7

An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

Latest material event: REVIVA PHARMACEUTICALS HOLDINGS, INC. was delisted from its exchange (Jul 10, 2026)

Timeline

Every material event, newest first. History is never overwritten.

  1. REVIVA PHARMACEUTICALS HOLDINGS, INC. was delisted from its exchange

    Jul 10, 2026

    Delisting effective

    • SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001742927 REVIVA PHARMACEUTICALS HOLDINGS, INC. 001-38634 19925 Stevens Creek Blvd., Suite 100 Cupertino CA CALIFORNIA 95014 (408) 501-8881 Common Stock 17 CFR 240.12d2-2(b) Aravind Menon Hearings Advisor 2026-07-10”

  2. REVIVA PHARMACEUTICALS HOLDINGS, INC. received a delisting notice from its exchange

    May 12, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing. As previously disclosed, the common stock of Reviva Pharmaceuticals Holdings, Inc. (the Company ) was not in compliance with the requirement under Nasdaq Listing Rule 5550(a)(2) (the Bid Price Requirement ) to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market ( Nasdaq ) and the Company had until May 11, 2026, which was the maximum extent of the discretionary authority of the Nasdaq Hearings Panel (the Panel ). Having not regained complia…”

  3. REVIVA PHARMACEUTICALS HOLDINGS, INC. received a delisting notice from its exchange

    Jan 20, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing. On January 20, 2026, the Nasdaq Hearings Panel (the Panel ) of the Nasdaq Stock Market LLC ( Nasdaq ) notified Reviva Pharmaceuticals Holdings, Inc. (the Company , we or us ) that the Panel has granted the Company s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the Bid Price Requirement ) for continued listing through March 27, 2026 (the Exception ). Pursuant to the Exception, the Company is…”

Company information

Founded
—
Employees (estimate)
—
Industry
Pharmaceutical Preparations
Subindustry
—
Listing
SEC lists the ticker RVPH on OTC.
SEC CIK
0001742927
Website
—
LinkedIn
—
Headquarters
CUPERTINO, CA
Also known as
Tenzing Acquisition Corp.
Legal entities
REVIVA PHARMACEUTICALS HOLDINGS, INC.

Sources

Every material source used to build this profile.

  • SEC Company Submissions (TIER 1 · UNVERIFIED)

    REVIVA PHARMACEUTICALS HOLDINGS, INC. — Pharmaceutical Preparations (SIC 2834) — CUPERTINO, CA
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing. As previously disclosed, the common stock of Reviva Pharmaceuticals Holdings, Inc. (the Company ) was not in compliance with the requirement under Nasdaq Listing Rule 5550(a)(2) (the Bid Price Requirement ) to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market ( Nasdaq ) and the Company had until May 11, 2026, which was the maximum extent of the discretionary authority of the Nasdaq Hearings Panel (the Panel ). Having not regained complia…
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing. On January 20, 2026, the Nasdaq Hearings Panel (the Panel ) of the Nasdaq Stock Market LLC ( Nasdaq ) notified Reviva Pharmaceuticals Holdings, Inc. (the Company , we or us ) that the Panel has granted the Company s request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the Bid Price Requirement ) for continued listing through March 27, 2026 (the Exception ). Pursuant to the Exception, the Company is…
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    X0203 0001354457 Nasdaq Stock Market LLC 0001742927 REVIVA PHARMACEUTICALS HOLDINGS, INC. 001-38634 19925 Stevens Creek Blvd., Suite 100 Cupertino CA CALIFORNIA 95014 (408) 501-8881 Common Stock 17 CFR 240.12d2-2(b) Aravind Menon Hearings Advisor 2026-07-10
    View source record

Status history

Every derived status, with the rule that produced it.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:29 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:13 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:34 PM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:46 PM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 11, 2026, 12:03 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:21 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.